Literature DB >> 27272816

The Value of Lymph Node Dissection in the Surgery of Colorectal Cancer Liver Metastases.

Andrea Bradatsch1, Peter Kornprat2, Heinz Bacher1, Herwig Cerwenka1, Johannes Haybaeck3, Hans-Jörg Mischinger1.   

Abstract

BACKGROUND/AIM: Liver resection is the best treatment for metastatic colorectal cancer (CRC). Hepatic lymph node metastases are considered as extrahepatic disease and represent an unfavorable prognostic factor. However, extrahepatic disease, when resectable, provides no contraindication for surgical therapy. The aim of this study was to evaluate the prevalence of hepatic lymph node involvement in our patients' cohort. PATIENTS AND METHODS: Twenty patients submitted to resection for colorectal liver metastases were studied prospectively. Three areas for lymph node dissection were defined and analyzed separately. Lymph nodes were examined by hematoxylin and eosin staining and immunohistochemistry for Pan-Keratin.
RESULTS: In average, 5 lymph nodes were harvested per patient. Macroscopic enlargement was not a definite sign for metastatic involvement. No morbidity or mortality was associated with lymphadenectomy. In our patients' collective, no cases of lymph node metastases occurred.
CONCLUSION: There is no evidence of a survival benefit after lymph node dissection in patients with CRC liver metastases in the literature. Systematic lymphadenectomy can, however, provide a prognostic tool to better plan further treatment. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Liver metastasis; colorectal cancer; liver surgery; lymph node dissection

Mesh:

Year:  2016        PMID: 27272816

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

2.  Selective versus routine lymphadenectomy in the treatment of liver metastasis from colorectal cancer: a retrospective cohort study.

Authors:  Daniel Pindak; Jana Pavlendova; Miroslav Tomas; Jozef Dolnik; Robert Duchon; Juraj Pechan
Journal:  BMC Surg       Date:  2017-04-04       Impact factor: 2.102

3.  Additional lymphadenectomy might not improve survival of patients with resectable metastatic colorectal adenocarcinoma of T4 stage, proximal location, poor/undifferentiation, or N3/N4 stages: a large population-based study.

Authors:  Yang-Yang Zhou; Qing-Wei Zhang; Jian Huang; Xia-Lin Yan; Chao Chen; Fan-Fan Xu; Xiao-Jing Du; Rong Jin
Journal:  J Cancer       Date:  2018-06-14       Impact factor: 4.207

4.  LncRNA CRNDE and lncRNA SNHG7 are Promising Biomarkers for Prognosis in Synchronous Colorectal Liver Metastasis Following Hepatectomy.

Authors:  Peixian Zhang; Lan Shi; Linjing Song; Yi Long; Kehua Yuan; Wanbao Ding; Lei Deng
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

5.  MicroRNA-133b expression inversely correlates with MET and can serve as an optimum predictive biomarker for patients of colorectal cancer.

Authors:  Yihang Guo; Gui Hu; Biao Xie; Ni Gong
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.